Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review

Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review

Liver cancer has the fourth highest mortality rate of all cancers worldwide, with hepatocellular carcinoma (HCC) being the most prevalent subtype. Despite great advances in systemic therapy, such as molecular-targeted agents, HCC has one of the worst prognoses due to drug resistance and frequent rec...

Full description

Bibliographic Details
Main Authors:	Kyoko Oura, Asahiro Morishita, Joji Tani, Tsutomu Masaki
Format:	Article
Language:	English
Published:	MDPI AG 2021-05-01
Series:	International Journal of Molecular Sciences
Subjects:	hepatocellular carcinoma tumor microenvironment immunotherapy immune checkpoint inhibitor molecular target agent adaptive cell transfer-based therapy
Online Access:	https://www.mdpi.com/1422-0067/22/11/5801

Similar Items

The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma
by: Kyoko Oura, et al.
Published: (2023-02-01)

MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review
by: Asahiro Morishita, et al.
Published: (2021-01-01)

Efficacy and outcome of molecular targeted therapies in elderly patients with hepatocellular carcinoma: Relative dose intensity associated with overall survival
by: Kyoko Oura, et al.
Published: (2023-12-01)

Management of hepatocellular carcinoma, an important cause of death in Japanese autoimmune hepatitis patients
by: Tomoko Tadokoro, et al.
Published: (2024-04-01)

Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology
by: Sandra Mirie Kang, et al.
Published: (2022-03-01)

Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma—A Review
by: Kyoko Oura, et al.
Published: (2020-11-01)

Giant cutaneous metastasis from hepatocellular carcinoma
by: Asahiro Morishita, et al.
Published: (2022-05-01)

Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma
by: Zhuomao Mo, et al.
Published: (2021-02-01)

Role of β-Catenin Activation in the Tumor Immune Microenvironment and Immunotherapy of Hepatocellular Carcinoma
by: Masahiro Morita, et al.
Published: (2023-04-01)

Tumor Microenvironment Composition and Related Therapy in Hepatocellular Carcinoma
by: Li Z, et al.
Published: (2023-11-01)

Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma
by: Naoshi Nishida
Published: (2021-07-01)

Neoadjuvant systemic therapy for hepatocellular carcinoma
by: R. Connor Chick, et al.
Published: (2024-03-01)

The Role of Long Non-Coding RNA and microRNA Networks in Hepatocellular Carcinoma and Its Tumor Microenvironment
by: Tingting Shi, et al.
Published: (2021-09-01)

A comprehensive study based on exosome-related immunosuppression genes and tumor microenvironment in hepatocellular carcinoma
by: Zhan Yang, et al.
Published: (2022-12-01)

Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
by: Anne Dyhl-Polk, et al.
Published: (2021-06-01)

Overexpression of SMS in the tumor microenvironment is associated with immunosuppression in hepatocellular carcinoma
by: Lin Xiang, et al.
Published: (2022-12-01)

DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma
by: Yunfei Chen, et al.
Published: (2021-07-01)

The Complexity of the Tumor Microenvironment in Hepatocellular Carcinoma and Emerging Therapeutic Developments
by: Antonella Argentiero, et al.
Published: (2023-12-01)

Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities
by: Carmelo Laface, et al.
Published: (2022-08-01)

Emerging treatment modalities for systemic therapy in hepatocellular carcinoma
by: Xin Qing, et al.
Published: (2021-08-01)

Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy
by: Jin Zhang, et al.
Published: (2023-03-01)

Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
by: Vito Longo, et al.
Published: (2019-10-01)

The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
by: Patrizia Leone, et al.
Published: (2021-05-01)

Immunosuppressive microenvironment in oral cancer: implications for cancer immunotherapy
by: Shalini K. Sureshbabu, et al.
Published: (2021-08-01)

Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma
by: Carmelo Laface, et al.
Published: (2023-01-01)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
by: Fei Yang, et al.
Published: (2022-01-01)

The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma
by: Liliana Montella, et al.
Published: (2021-07-01)

Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma
by: Ming Zhao, et al.
Published: (2023-05-01)

Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages
by: Jingyi Zhou, et al.
Published: (2021-02-01)

The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
by: Landon L. Chan, et al.
Published: (2023-10-01)

Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma
by: Wanying Shen, et al.
Published: (2022-10-01)

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
by: Nikolaos Machairas, et al.
Published: (2022-04-01)

Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
by: Francesco Tovoli, et al.
Published: (2020-10-01)

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
by: Samantha M. Ruff, et al.
Published: (2023-06-01)

Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody
by: Masahiro Morita, et al.
Published: (2021-06-01)

Complications of immunotherapy in advanced hepatocellular carcinoma
by: Young-Gi Song, et al.
Published: (2024-03-01)

Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy
by: Kyoko Oura, et al.
Published: (2023-06-01)

Immune checkpoint inhibitors for hepatocellular carcinoma – A game changer in treatment landscape
by: Tsung-Hao Liu, et al.
Published: (2022-08-01)

Simultaneous and Sequential Use of Molecular Targeted Agents Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Real-World Practice in China
by: Li J, et al.
Published: (2023-06-01)

Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options
by: Zuzanna Sas, et al.
Published: (2022-03-01)